Mycobacterium abscessus complex (MABSC) presents significant therapeutic challenges with poor clinical outcomes. This article discusses the promise and pitfalls of interpreting dual β-lactam (DBL) success in MABSC infections. The need for safer, more effective, and evidence-based treatment options is highlighted. While DBL therapy has shown some efficacy, its interpretation requires caution due to the complexity of MABSC resistance mechanisms and the potential for misleading in vitro results. Understanding the nuances of DBL therapy and its limitations is crucial for guiding clinical decisions and developing robust treatment strategies for this difficult-to-treat pathogen. Further research is essential to validate optimal regimens.
Key note: Exercise caution when interpreting dual β-lactam success in MABSC due to complex resistance mechanisms and the need for evidence-based treatment.